[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myoepithelial-tumor":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Myoepithelial Tumor",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[11],"2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",[],[]]